Post-translational modification of proteins may influence their interactions with other plasma proteins, as well as having an effect on many aspects of the metabolism of the protein, such as receptor binding, tissue uptake, degradation and excretion. Many post-translational modifications occur in a physiological context, while others are specific for certain diseases, which is why they are of diagnostic importance in clinical proteomics. Analytical approaches to the study of post-translational modifications and protein complexes through the combined use of on-chip immunological affinity purification on a surface-enhanced laser desorption/ionisation platform and subsequent mass spectrometry are illustrated in the author's own work relating to plasma transthyretin (TTR) and retinol-binding protein (RBP). In those studies, both the aspects of post-translational modifications of TTR and the formation of a protein complex between TTR and RBP have been discussed. Such aspects are of diagnostic interest in clinical proteomics, especially with regard to the modification of TTR in relation to the occurrence of amyloidotic diseases.
INTRODUCTION
The proteome, defined as the protein complement expressed by a genome, implies a static nature but in reality is highly dynamic. The types of proteins expressed, their abundance and state of modification, to name but few aspects, are all dependent on the physiological or pathophysiological state of the cell or the tissue. Thus, the proteome reflects the cellular state or the external conditions encountered by an organism. Therefore, proteomics may be defined as the different methodologies used to describe the structural diversity of proteins and the correlation of this diversity with the underlying biological processes. Despite the fact that the coding occurs on a mere 30,000-40,000 genes, the corresponding proteome is much more complex than this perhaps implies. Events such as alternative splicing and post-translational modifications generate a highly diverse set of proteins that could exceed a million distinct molecular species. In many cases, it is likely that concentrations of specific proteins do not change significantly, but rather their function is modulated by post-translational modifications.
simple proteolysis or by various sophisticated post-translational modifications. These modifications range from the widespread, such as glycosylation, phosphorylation, ubiquitination and methylation, to the less frequent ones, such as glutathionylation, hydroxylation, sulphation and transglutamination. It has been estimated that more than 50 per cent of all known proteins are glycosylated. 5 The small differences frequently existing between two proteins, for example a single amino acid modification, invariably exerts important influences on the function of the protein. Functions such as secretion, plasma transport, receptor binding, degradation and excretion may be influenced, in addition to protein-protein complex formation. Thus, posttranslational modification can create a dynamic composite 'library' of properties that rapidly respond to physiological or pathophysiological stimuli. [6] [7] [8] [9] [10] The protein-protein interaction process has gained considerable interest with regard to intracellular communication but is also of great importance in the plasma. 11, 12 Many of the plasma proteins are known to exist in multi-protein complexes and thereby to affect functions such as plasma transport, receptor binding, degradation and excretion, as with glomerular filtration. 13 Examples for these proteins are insulinlike growth factor-binding protein, tumour necrosis factor-binding protein and transthyretin (TTR). [14] [15] [16] Since TTR fulfils both criteria, in that it is found on its own with post-translational modifications as well as in a proteinprotein complex with retinol-binding protein (RBP), it is ideal for use in illustrating these aspects.
Thus, monitoring post-translational modifications and protein complexes are two foremost tasks because of their potential impact on the understanding of protein function in health and disease. These aspects are described by the terms 'heteromics' and 'interactomics', respectively, within the umbrella term of 'functional proteomics', with the aim of characterising the structural as well as functional properties of proteins, such as their interaction with other proteins. 17, 18 This provides the basis for a substantial step forward in diagnostics, especially with regard to personalised medicine. 19, 20 Such information will improve researchers' ability to make early diagnoses and develop prognostic indices and novel therapies. Despite the great importance of post-translational modifications and protein complexes for biological function, however, the extensive study of these aspects has been hampered by the lack of suitable highthroughput methods.
IMMUNOASSAY-BASED ANALYTICAL APPROACHES TO CHARACTERISING POST-TRANSLATIONAL MODIFICATIONS AND PROTEIN COMPLEXES
The microheterogeneity of proteins has traditionally been investigated using twodimensional electrophoresis. It is still a key technology, providing global views of changes in post-translational modifications. Post-translational modifications that result in a change in the isoelectric point and/or the molecular mass enable identification, moreover the separation of glycoproteins into the typical trains of protein spots is also possible. 21, 22 Under these denaturing separation conditions, however, protein complexes cannot be characterised.
The most promising analytical approach for the characterisation of both post-translational modifications and protein complexes is the use of highaffinity antibodies to capture both proteins of interest and their interacting proteins. Antibodies are very appropriate receptor elements in a protein-detection array, as they possess the specificity required to identify a target epitope. Traditionally, antibodies have been used to determine the characteristics of a gene Challenges in proteomics include the large number of protein modifications and protein-protein interactions product -such as its tissue distribution, cellular localisation, post-translational modifications, expression levels and complexes formed -using standard techniques such as immunohistochemistry, Western blots and immunoprecipitation. As shown in Figure 1 , a TTR Western blot after one-dimensional electrophoresis is unable to discriminate between slightly modified molecules, and only one single band at 14 kDa is visible.
Currently, antibody chips are under investigation to study the expression level of selected proteins using a quantitative conformation of antigen-antibody binding. This is comparable to a miniaturised enzyme-linked immunosorbent assay (ELISA) platform. To monitor post-translational modifications in such assays, the modifications must be known and specific antibodies for interaction with these modifications have to be available. 23 To investigate isoforms of proteins, as well as protein complexes, various approaches can be used to combine the specific affinity interaction with mass spectrometry (MS). This includes the traditional approach of immunoprecipitation or the capture of antigen with an immobilised affinity column. MS analysis can be performed directly on the column-packing material or after elution of the analyte from the column material. 24 Affinity chromatography in combination with different detection devices is another methodological approach. 25 These methods have been successfully applied to characterising the microheterogeneity of plasma peptides and proteins, such as amyloid-â peptides, â2-microglobulin, TTR and RBP, in healthy and diseased states, [26] [27] [28] [29] [30] as well as for protein-protein interactions. 31, 32 The surface-enhanced laser desorption/ ionisation (SELDI) platform can be readily adapted for developing an immunoassay format. This approach, using antibodies as an affinity capture device, has successfully been used to detect and quantify different proteins in complex biological mixtures by MS. Specific proteins known to exist in different molecular variants are amyloid-â and serum amyloid-AE. 33, 34 Unlike current ELISA technology, which uses an indirect detection mechanism by 'sandwiching' the targeted protein with antibodies, the SELDI-based immunoaffinity assay allows for direct detection without tags. The antibody used as bait recognises an epitope in different isoforms of TTR. This direct sampling provides a unique advantage over the more traditional ELISA methods, in which the resulting signal is a weighted average of all the bound species. Alternatively, surface plasmon resonance-biomolecular interaction analysis (SPR-BIA) can be used by coupling the Biacore instrument with the mass spectrometer to characterise proteins and protein-protein interactions 35, 36 The discriminating power achievable with the combination of affinity purification with MS is shown in a direct comparison between Western blotting ( Figure 1 ) and SELDI-time-offlight MS immunoassay (Figure 2 ). The small mass differences observed with MS cannot be detected by the combination of one-dimensional electrophoresis and immunological detection. Better resolution of the microheterogeneous variants of TTR can be obtained using two-dimensional electrophoresis 37 (www.expasy.org/cgi-bin/map1) in combination with Western blotting, but, again, this approach is limited by a similar low mass accuracy. The combination of one-dimensional electrophoresis with subsequent Western blot combines the same steps as on-chip immunoaffinity enrichment and MS but in a different sequence: first the immunological interaction and then the mass resolution.
METHODOLOGICAL CONSIDERATIONS
When using an on-chip immunoassay format, it is important that the protein chip retains the antibody in an active state at high density. Thus, the solid surface of the substrate has to be modified to achieve maximum activity and binding capacity. This is best achieved with reactive surfaces that can covalently crosslink to proteins. These aspects demand consideration when developing protein chips. 23, 38, 39 In general, polyclonal antibodies normally have the ability to bind different protein isoforms, regardless of their differences, and can therefore often be used to analyse homologues. 40 This is clearly an advantage for studying the microheterogeneity of proteins, but needs further characterisation. When using polyclonal antibodies in experiments to characterise protein complexes, however, it should be kept in mind that non-specific cross-reactivity with other proteins is more pronounced than with monoclonal antibodies. Other important aspects in using monoclonal or polyclonal antibodies in such experiments are the characteristics of functionality, such as stability, affinity and specificity. Extensive testing before use is certainly necessary. Based on studies relating to microarrays, only 5-20 per cent of the commercial antibodies are suitable, with some being suitable in one microarray format but not in another. 41, 42 TTR AND RBP TTR (formerly called prealbumin) belongs to a group of proteins including thyroxine-binding globulin and albumin which bind and transport thyroid hormones in the blood. It is a single polypeptide chain of 127 amino acids (14 kDa) and is present in the plasma as a tetramer of non-covalently bound monomers. The major sites of TTR synthesis are the liver and choroid plexus. [43] [44] [45] Under physiological conditions, the macromolecular complex plays an important physiological role in vitamin A homeostasis, because it binds the specific transport protein for retinol, the lipocalin RBP. 46, 47 This reduces the glomerular filtration of the low molecular weight transport protein (21 kDa) in the kidneys. Any TTR or RBP molecules that are filtered are rapidly bound to megalin, the multi-ligand receptor expressed on the luminal surface of the renal proximal tubules, and are thus internalised. Therefore, under physiological conditions, TTR and RBP are present only in trace amounts in urine, if at all. 48, 49 With regard to nutrition, TTR is a so-called visceral protein which is synthesised in the liver in response to nutritional supply. TTR plasma levels have thus been proposed as sensitive biochemical parameters of subclinical protein malnutrition because both the adequacy and levels of protein, as well as energy intakes, are reflected in plasma levels. Plasma levels of TTR, are also affected by acute and chronic diseases associated with an acute-phase response, however. Under these conditions, liver activity is converted to the synthesis of acute-phase response proteins, resulting in a dramatic drop in visceral proteins, despite nutritional support.
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PHYSIOLOGICAL AND CLINICAL SIGNIFICANCE OF POST-TRANSLATIONAL MODIFICATIONS IN TTR
The TTR variants described thus far have mostly been associated with variable degrees of cardiac and/or neural tissue amyloid deposits in severe diseases such as familial amyloidotic polyneuropathy, senile systemic amyloidosis and euthyroid hyperthyroxinaemia. 50, 51 Mutations in the Homeostatic processes in plasma transport of vitamin A are effected by protein-protein interactions amino acid sequence of TTR are therefore of great clinical interest. 52 In general, mutations appear to be distributed randomly within the molecule and most of these mutations lead to the synthesis of TTR molecules which have the tendency to form insoluble protein aggregates. These so-called amyloid deposits accumulate in the extracellular regions of various organs. Although the role of amyloid deposits in the pathogenesis of the disease is not clear, preventing their formation or promoting their disaggregation is necessary to control the development of clinical symptoms. 53, 54 The reported isoforms of TTR result when the Cys-10 residue forms a mixed disulphide with the amino acid cysteine, the peptide glutathione or the peptide cysteinyl-glycine. Recent studies show that the most prevalent modification of TTR renders it substantially more amyloidogenic than the non-cysteinylated form at pH 5. 55 The possible importance of this as a risk factor for the onset of senile systemic amyloidosis remains to be elucidated. Additionally, Cys-10 adducts of Shomocysteine and TTR have been detected in the plasma of humans with hyperhomocysteinaemia. 56 Recently, a truncated form of TTR has been described in combination with two other proteins as a valid marker for the early diagnosis of ovarian carcinoma. 57 These findings support the importance of a high-throughput diagnostic approach to characterising isoforms of TTR.
THE TTR-RBP COMPLEX
It has been shown that recognition between the two members of the protein complex is correlated with the retinoid ligand to RBP. In the case of the retinoid fenretinide, which has an exposed bulky hydroxyphenyl group on the protein surface, the RBP concerned shows a very low affinity for TTR. The apo-RBP also has a reduced affinity for TTR. With regard to TTR, one mutation with the substitution Ile 84 ! Ser results in a reduced affinity for RBP. 58 It is not known, however, if post-translational modifications affect the affinity of the interaction of the TTR-RBP complex. 47 
IMPROVED RESOLUTION OF POST-TRANSLATIONAL MODIFICATIONS THROUGH ON-CHIP IMMUNOLOGICAL ENRICHMENT
In general, due to its isoelectric point, TTR can be efficiently enriched on a strong anion exchange surface (SAX, Ciphergen Biosystems Inc., Palo Alto, CA, USA). As depicted in Figure 2a , however, the structure of the complex in the TTR mass range 13,700-14,100 Da indicates mass differences that cannot be attributed with certainty to TTR. The selective on-chip enrichment through polyclonal TTR antibody (Dakocytomation, Denmark)-activated chip surfaces results in a clearly improved signal intensity and a better separation of individual signals. In addition to this, it improves the certainty with which the protein can be identified. Beside the native variant of TTR (13,755 Da), three variants with higher molecular weights are often observed. The other ion peaks have been found to show molecular sizes of 120, 180 and 300 Da greater than native TTR, representing Cys-10 adducts for S-cysteine (TTR-Cys-10-S-S-Cys, mass ¼ 13,875 Da), S-cysteinylglycine (TTR-Cys-10-S-S-CysGly, mass ¼ 13,935) and S-glutathione (TTR-Cys-10-S-S-SG, mass ¼ 14,053), respectively. Additionally, in most samples, a fragment of TTR (12,820 Da) is visible at low intensities (see the arrow in Figure 2b ). This fragment has recently been identified as a form of TTR truncated at the Nterminal end by ten amino acids.
57 Figure 3 shows a similar pattern of TTR microheterogeneity to that seen in Figure 2b , but in this sample a split signal is observed with a mass difference of 30 Da, resulting from a point mutation. This is clearly visible in the dominant cysteinylated form of TTR but is also Transthyretin exists in diverse molecular variants of clinical and diagnostic importance present in the native and the glutathionylated variant, as indicated by the broadening of the peaks. Due to the limited number of available plasma samples showing such a mutation, it is difficult to evaluate possible differences in posttranslational modification. The samples studied were found to be well in the range of normal plasma samples. Furthermore, no differences in the interaction between TTR and RBP were observed. So far, only one point mutation (substitution Ile 84 ! Ser) among the 70 known mutations has been found to affect the interaction between TTR and RBP. 58 
ON-CHIP MODIFICATION
zAfter on-chip affinity enrichment, a further characterisation of the nature and the extent of the modification is possible, because at this point the modification does not interfere with the antibody-antigen interaction. This would include, for example, on-chip deglycosylation of glycoproteins for the estimation of the extent and type of glycoslyation, treatment with proteases to obtain sequence information through peptide mapping 59, 60 and treatment with dithiothreitol (DTT) to determine the extent of disulphide linkage. 61 This latter aspect can be applied to TTR. The shift in the mass spectrum of TTR variants due to treatment with DTT after its immunological enrichment on the chip (Figure 2c) indicates that the adducts are formed via the disulphide linkage at Cys-10.
THE TTR-RBP COMPLEX
If a protein complex is present, the proteins involved in this complex can be extracted together through the use of antibodies against one of the proteins in Protein phenotype is an important aspect in personalised diagnostics the complex. In the case of TTR and RBP, antibodies against either protein should be able to achieve this. Interestingly, however, when the complex is enriched through polyclonal TTR antibodies, no RBP can be detected (Figure 4a) . If a polyclonal antibody against RBP (DakoCytomation) is used as bait, however, both RBP and TTR are retained on the chip surface (Figure 4b ). This is in contrast to results in which a TTR antibody was found to be able to enrich both TTR and RBP. 62 It can be speculated that these differences might be due to concentration differences between TTR (higher) and RBP (lower). Alternatively, this discrepancy might be explained by the fact that, since TTR in plasma occurs as a homotetramer with and without RBP, 47 the TTR antibody might only be able to detect TTR that is not carrying RBP. This is possibly because the presence of RBP might make a binding epitope inaccessible to the antibody. This exemplifies, on the one hand, the limitations of antibodies under certain circumstances -as well as possible individual antibody-specific differences but, on the other hand, this fact might also offer results that make the discovery of new biological phenomena possible.
CONCLUSION
As depicted in the example of TTR and RBP, the combination of immunoaffinity methods for the purification of microheterogeneous proteins and protein complexes, and their identification by MS, is very efficient. Using the SELDI platform, a rapid, highly reproducible and cost-effective system for the determination of molecular variants of microheterogeneous proteins and protein complexes can be established. This is of importance in 'second phase' proteomics, which is characterised by the repetitive investigation of the same protein to validate the protein phenotype in large population-based studies and provides the basis for substantial diagnostic progress with regard to personalised medicine. 19, 20 With specific regard to TTR, this approach might not only be of importance in the diagnosis of TTRrelated amyloidosis but may also have potential use as an alternative or new biomarker for the metabolism of TTR itself, and as a protein complex with RBP, for use in nutrition-related disease, the diagnosis of kidney function and as a possible marker for cancer. 
